NCT01628445

Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

Phase 3 Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: University of Manitoba · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Liraglutide is a GLP1 agonist used in the treatment of Type 2 diabetes and is is asociated with improved blood glucose control, weight loss and low rates of hypoglycemia when used alone or in combination with metformin. Liraglutide has not been extensively tested in people with type 2 diabetes who are taking relatively large doses of insulin (\>50 U/day). Often these patients are insulin resistant and despite using large doses of insulin are not able to achieve glucose targets. The rationale for this study is to assess if the addition of liraglutide in addition to usual care versus placebo can improve blood glucose levels in people not achieving a target HbA1C of less than 7.0%.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	liraglutide	liraglutide titrated to 1.8 mg sc daily
DRUG	placebo injection	placebo injected sc daily volume equal to active comparator

Timeline

• Start date: 2012-08-01
• Primary completion: 2015-11-01
• Completion: 2015-11-01
• First posted: 2012-06-26
• Last updated: 2016-01-21

Locations

1 site across 1 country: Canada